After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded31 May 2016

Publisherfeeds.transistor.fm ↗

Handlerec:13866400

Show notes

Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter. Why? Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same – Twitter and Square. Well, medtech’s version of Jack Dorsey might be Duke Rohlen. Duke led FoxHollow Technologies...[read more]Related StoriesWhy Intersect ENT is an Example of Hope for the Medtech IndustryAre Medical Device Models the Key to Building a Lean Medtech Startup?Substantial and Sustainable – 2 Words That Medtech Companies Should Get Used To

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.